Tags

Type your tag names separated by a space and hit enter

Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.
Transbound Emerg Dis. 2021 May; 68(3):1111-1124.TE

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) as a pandemic has shaken the global health system and economy by their roots. This epidemic is still spreading and showing no signs of decreasing trend. Vaccination could be the only effective and economical means to control this pandemic. A number of research institutions and pharmaceutical companies have plunged into the race of vaccine development against COVID-19 which are in various stages of development. An intriguing fact of coronavirus infections is that in every decade of the 21st century there is a new major coronavirus epidemic, namely, severe acute respiratory syndrome (SARS) in 2002, Middle East respiratory syndrome (MERS) in 2012, and now COVID-19; and such epidemics are expected in future too. Since most of the biological characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are still obscure, the scientists are relying on the information available on SARS-CoV and to some extent on MERS-CoV for designing and developing COVID-19 vaccines. But there is a need of vigorous testing for immunogenicity, safety, efficacy, and level of protection conferred in the hosts. This review focuses on the challenges and prospects of vaccine development against COVID-19. It highlights seriousness, bottlenecks in vaccine development, possible vaccine candidates, different vaccine strategies, safety evaluation issues, and vaccine production processes pertaining to COVID-19 based on the knowledge acquired on SARS and MERS vaccine development in the past.

Authors+Show Affiliations

Department of Veterinary Microbiology, College of Veterinary and Animal Sciences, GBPUAT, Pantnagar, India.ICAR-Central Avian Research Institute, Bareilly, India.ICAR-Central Avian Research Institute, Bareilly, India.Department of Microbiology, Jawaharlal Nehru Institute of Medical Science, Porompat, India.Sher-e-Kashmir University of Agricultural Sciences and Technology-Kashmir, Srinagar, India.ICAR-Central Avian Research Institute, Bareilly, India.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32815655

Citation

Begum, Jubeda, et al. "Challenges and Prospects of COVID-19 Vaccine Development Based On the Progress Made in SARS and MERS Vaccine Development." Transboundary and Emerging Diseases, vol. 68, no. 3, 2021, pp. 1111-1124.
Begum J, Mir NA, Dev K, et al. Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development. Transbound Emerg Dis. 2021;68(3):1111-1124.
Begum, J., Mir, N. A., Dev, K., Buyamayum, B., Wani, M. Y., & Raza, M. (2021). Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development. Transboundary and Emerging Diseases, 68(3), 1111-1124. https://doi.org/10.1111/tbed.13804
Begum J, et al. Challenges and Prospects of COVID-19 Vaccine Development Based On the Progress Made in SARS and MERS Vaccine Development. Transbound Emerg Dis. 2021;68(3):1111-1124. PubMed PMID: 32815655.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development. AU - Begum,Jubeda, AU - Mir,Nasir Akbar, AU - Dev,Kapil, AU - Buyamayum,Bidyarani, AU - Wani,Mohd Yaqoob, AU - Raza,Meesam, Y1 - 2020/09/23/ PY - 2020/08/14/revised PY - 2020/05/21/received PY - 2020/08/15/accepted PY - 2020/8/21/pubmed PY - 2020/8/21/medline PY - 2020/8/21/entrez KW - COVID-19 KW - MERS KW - SARS KW - spike protein KW - vaccine candidate KW - vaccine development SP - 1111 EP - 1124 JF - Transboundary and emerging diseases JO - Transbound Emerg Dis VL - 68 IS - 3 N2 - The outbreak of coronavirus disease 2019 (COVID-19) as a pandemic has shaken the global health system and economy by their roots. This epidemic is still spreading and showing no signs of decreasing trend. Vaccination could be the only effective and economical means to control this pandemic. A number of research institutions and pharmaceutical companies have plunged into the race of vaccine development against COVID-19 which are in various stages of development. An intriguing fact of coronavirus infections is that in every decade of the 21st century there is a new major coronavirus epidemic, namely, severe acute respiratory syndrome (SARS) in 2002, Middle East respiratory syndrome (MERS) in 2012, and now COVID-19; and such epidemics are expected in future too. Since most of the biological characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are still obscure, the scientists are relying on the information available on SARS-CoV and to some extent on MERS-CoV for designing and developing COVID-19 vaccines. But there is a need of vigorous testing for immunogenicity, safety, efficacy, and level of protection conferred in the hosts. This review focuses on the challenges and prospects of vaccine development against COVID-19. It highlights seriousness, bottlenecks in vaccine development, possible vaccine candidates, different vaccine strategies, safety evaluation issues, and vaccine production processes pertaining to COVID-19 based on the knowledge acquired on SARS and MERS vaccine development in the past. SN - 1865-1682 UR - https://www.unboundmedicine.com/medline/citation/32815655/Challenges_and_prospects_of_COVID_19_vaccine_development_based_on_the_progress_made_in_SARS_and_MERS_vaccine_development_ L2 - https://doi.org/10.1111/tbed.13804 DB - PRIME DP - Unbound Medicine ER -